Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2016 · 10-Q
Revenue$936.00K$936.00K−29.9% vs Q3 2015 Net Income-$1.84M-$1.84MN/M vs Q3 2015 EPS Diluted-$6.92-$6.92N/M vs Q3 2015 Operating Income-$1,816,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,124,000N/M Margins · derivedOperating margin-194.0%+40.3 pt vs Q3 2015
Net margin-196.5%+39.6 pt vs Q3 2015
ended Sep 30, 2016 · filed Oct 26, 2016 · 26 d after period end